Monday, October 26, 2026 · Daily editionET --:--:--

Under way, not recruiting

Robotic vs Open Nephrectomy for ADPKD

NCT07355114 · University of Bologna · Updated 21 Jan 2026

What is being tested
Not stated
For
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Kind of study
Watches patients without assigning a treatment. No drug phase (a device or procedure study).
Who can join
Ages 18 years and older. About 57 people. The full rules are on the registry page.
Where
Italy
When
Starts or started 1 Jan 2023, ends 1 Jan 2028. Registered 21 Jan 2026.
Results
None posted yet.

In the researchers' words

The goal of this observational prospective cohort study is to evaluate the feasibility, safety, and postoperative outcomes of robotic-assisted unilateral native nephrectomy using the Medtronic Hugo™ RAS system compared with the open surgical approach in patients with autosomal dominant polycystic kidney disease (ADPKD) The main question(s) it aims to answer are: Is robotic-assisted unilateral nephrectomy with the Hugo™ RAS system feasible and safe in patients with ADPKD? Does robotic-assisted nephrectomy provide comparable or improved postoperative outcomes (e.g., complications, transfusion rates, length of hospital stay) compared with open nephrectomy? Researchers will compare robotic-assisted unilateral nephrectomy (Hugo™ RAS) with open unilateral nephrectomy to see if the robotic approach results in similar morbidity with shorter hospital stay, despite longer operative times. Participants are adult patients with ADPKD undergoing unilateral native nephrectomy at a single tertiary transplant center, most of whom have end-stage renal disease and are candidates for or recipients of kidney transplantation. Both male and female patients were included; patients undergoing bilateral nephrectomy were excluded.
ClinicalTrials.gov, NCT07355114

Sites

  • IRCSS Azienda Ospedaliero-Universitaria di BolognaBologna, Bo, Italy